With demand for GlaxoSmithKline’s lupus-fighter Benlysta growing in the U.S. and approval of a new formulation expected later this year, the U.K., drugmaker says it is time to bring on more capacity at a U.S. manufacturing facility.
GSK today said it will invest $139 million at its biopharma site in Rockville, Maryland, allowing it to expand bulk drug capacity by about 50% for the intravenous drug, as well as a new subcutaneous formulation for which GSK hopes to get approval later this year. Work has started on the project and the added production is expected to be online in 2019.
The announcement came on the first day of Lupus Awareness Month.
Approved in 2014, Benlysta continues to be a growing product for GSK, increasing at least 18% per year in the U.S. on a constant exchange rate basis, the company said. Last year, GSK reported $377 million (£277 million) in sales for the drug in the U.S., and revenues for the med grew even more this quarter, up 22% to $117.7 million (£91 million) worldwide.
This is the second big expansion for the Rockville site, located outside of Washington, D.C., where about 400 people work. In December, GSK opened a $50 million vaccine R&D center at the facility where scientists will research potential deadly outbreaks.
It is also the second major manufacturing expansion announced by the drugmaker in the last couple of months. In March, it said it would build a $175 million biopharma facility at its site in Marburg, Germany, so it can expand production of the meningococcal B shot Bexsero. GSK expects to start validation runs at that facility in the third quarter of 2020.
By Eric Palmer
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
